Multiple myeloma
Conditions
Interventions
Study drug will be administered at the last dose and schedule received on the previous study.
Subjects will receive treatment with study drugs and pre-medications according to the previous
study requi
Sponsors
Mckiver A Popa Mihaela
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participated in a previous elotuzumab protocol and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol. Subjects must be able to tolerate study therapy. Receiving elotuzumab and/or other study drugs at the time of signature of informed consent.
Exclusion criteria
Exclusion criteria: All subjects previously discontinued from an elotuzumab study for any reason. Subjects not receiving clinical benefit from previous study therapy. Subjects who are not medically well enough to receive study therapy as determined by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of subjects who received at least one dose of elotuzumab or backbone therapy (other study drugs) and the duration of treatment will be collected. | — |
Secondary
| Measure | Time frame |
|---|---|
| In this study, all SAEs, Grade 5 AEs, AEs previously not reported, AEs leading to discontinuation will be collected. Adverse events and other symptoms will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE). | — |
Countries
Australia, Belgium, Canada, Greece, Hungary, Italy, Japan, Poland, Romania, Spain, Turkey, UK, USA
Contacts
Public ContactMihaela Mckiver
Bristol-Myers Squibb
Outcome results
None listed